Related Experiment Video
Updated: Jun 1, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice
Jingmin Gu1, Jing Zuo, Liancheng Lei
1College of Animal Science and Veterinary Medicine, Jilin University; Changchun, China.
Abstract:
The endolysin LysGH15, derived from staphylococcal phage GH15, has a wide lytic spectrum and strong lytic activity against Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA), in vitro and in vivo. Here, the ability of lethal MRSA to induce mRNA levels of interleukin-6 (IL-6), interleukin-4 (IL-4), and interferon-γ (IFN-γ) in spleen tissues of mice was studied. A large number of bacteria were detected in spleens. The bacteria caused elevated expression levels of these three cytokines. Administration of LysGH15 significantly reduced the number of bacteria and the levels of IL-6, IL-4, and IFN-γ mRNA in spleen cells compared with those in untreated mice at 24 h (P < 0.05). LysGH15 can eliminate a large number of bacteria and effectively alleviate inflammation induced by infection with lethal MRSA.
Insights
The endolysin LysGH15 effectively reduced Staphylococcus aureus (MRSA) bacterial load and inflammation in mouse spleen tissues. This phage-derived protein shows promise for treating severe MRSA infections.
Area of Science:
- Microbiology
- Immunology
- Biotechnology
Background:
- Staphylococcus aureus, particularly methicillin-resistant strains (MRSA), poses a significant public health threat.
- MRSA infections can lead to severe systemic inflammation, characterized by elevated cytokine levels.
- Endolysins, such as LysGH15, are bacteriophage-derived proteins with potent antimicrobial activity.
Purpose of the Study:
- To investigate the impact of lethal MRSA infection on cytokine mRNA expression in mouse spleen tissues.
- To evaluate the efficacy of the endolysin LysGH15 in reducing bacterial load and modulating inflammatory responses in vivo.
- To assess LysGH15's therapeutic potential against MRSA-induced inflammation.
Main Methods:
- Induction of lethal MRSA infection in mouse models.
- Quantification of bacterial load in spleen tissues.
- Measurement of mRNA expression levels for interleukin-6 (IL-6), interleukin-4 (IL-4), and interferon-γ (IFN-γ) in spleen cells.
- Administration of LysGH15 and comparison of outcomes with untreated control groups.
Main Results:
- MRSA infection led to a significant increase in IL-6, IL-4, and IFN-γ mRNA levels in mouse spleen tissues.
- Treatment with LysGH15 significantly reduced the bacterial burden in the spleen.
- LysGH15 administration markedly decreased the elevated mRNA levels of IL-6, IL-4, and IFN-γ compared to controls.
- These effects were observed 24 hours post-treatment (P < 0.05).
Conclusions:
- The endolysin LysGH15 effectively eliminates a substantial number of MRSA bacteria.
- LysGH15 demonstrates significant anti-inflammatory properties by alleviating cytokine dysregulation during MRSA infection.
- LysGH15 represents a promising therapeutic agent for combating severe MRSA infections and associated inflammation.
